Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.

Journal of experimental & clinical cancer research : CR - 2 Jun 2017

Hujber Zoltán, Petővári Gábor, Szoboszlai Norbert, Dankó Titanilla, Nagy Noémi, Kriston Csilla, Krencz Ildikó, Paku Sándor, Ozohanics Olivér, Drahos László, Jeney András, Sebestyén Anna

Abstract excerpt

BACKGROUND: Multiple studies concluded that oncometabolites (e.g. D-2-hydroxyglutarate (2-HG) related to mutant isocitrate dehydrogenase 1/2 (IDH1/2) and lactate) have tumour promoting potential. Regulatory mechanisms implicated in the maintenance of oncometabolite production have great interest. mTOR (mammalian target of rapamycin) orchestrates different pathways, influences cellular growth and metabolism....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Fibrosarcoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutarates

Share to Lactic Acid

Share to Mechanistic Target of Rapamycin Complex 1

Share to Mice, SCID

Share to Sirolimus

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 28578659
DOI: 10.1186/s13046-017-0544-y
PMCID: PMC5457553

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.PMID 28578659Read ↗

Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathwaySemantic proximity Read ↗

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.Semantic proximity Read ↗

mTORC2 in the center of cancer metabolic reprogramming.Semantic proximity Read ↗

Oncometabolite D-2-hydroxyglutarate - dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexiaSemantic proximity Read ↗

Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibitionSemantic proximity Read ↗

Advances in Understanding of Metabolism of B-Cell Lymphoma: Implications for TherapySemantic proximity Read ↗

The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistanceSemantic proximity Read ↗

Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation.Semantic proximity Read ↗

In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors.Semantic proximity Read ↗

IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.Semantic proximity Read ↗

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.Semantic proximity Read ↗

Robust detection of oncometabolic aberrations by <sup>1</sup> H- <sup>13</sup> C heteronuclear single quantum correlation in live cells and intact tumors <i>ex-vivo</i>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.